MA56098B1 - Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 - Google Patents

Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1

Info

Publication number
MA56098B1
MA56098B1 MA56098A MA56098A MA56098B1 MA 56098 B1 MA56098 B1 MA 56098B1 MA 56098 A MA56098 A MA 56098A MA 56098 A MA56098 A MA 56098A MA 56098 B1 MA56098 B1 MA 56098B1
Authority
MA
Morocco
Prior art keywords
immunomodulators
heterocyclic
well
pdl1 inhibitors
inhibitors
Prior art date
Application number
MA56098A
Other languages
English (en)
Other versions
MA56098A (fr
Inventor
Edgar Jacoby
Gowan David Craig Mc
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56098A publication Critical patent/MA56098A/fr
Publication of MA56098B1 publication Critical patent/MA56098B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs de pd-l1 contenant de la pyridinone, des compositions pharmaceutiques comprenant ces composés, des procédés chimiques pour préparer ces composés, et leur utilisation dans le traitement de maladies infectieuses et du cancer. Formule (i).
MA56098A 2019-06-07 2020-06-05 Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 MA56098B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19179072 2019-06-07
PCT/EP2020/065646 WO2020245372A1 (fr) 2019-06-07 2020-06-05 Immunomodulateurs hétérocycliques utilisés comme inhibiteur de point de contrôle pdl1

Publications (2)

Publication Number Publication Date
MA56098A MA56098A (fr) 2022-04-13
MA56098B1 true MA56098B1 (fr) 2023-10-31

Family

ID=66793871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56098A MA56098B1 (fr) 2019-06-07 2020-06-05 Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1

Country Status (17)

Country Link
US (1) US20220259186A1 (fr)
EP (1) EP3980413B1 (fr)
JP (1) JP2022535879A (fr)
KR (1) KR20220017942A (fr)
CN (1) CN113966329A (fr)
AU (1) AU2020286962A1 (fr)
BR (1) BR112021023780A2 (fr)
CA (1) CA3138494A1 (fr)
ES (1) ES2956866T3 (fr)
HR (1) HRP20230873T1 (fr)
HU (1) HUE063236T2 (fr)
MA (1) MA56098B1 (fr)
MD (1) MD3980413T2 (fr)
MX (1) MX2021015048A (fr)
PL (1) PL3980413T3 (fr)
RS (1) RS64681B1 (fr)
WO (1) WO2020245372A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2642074T3 (es) * 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3601258B1 (fr) * 2017-03-27 2023-08-30 Bristol-Myers Squibb Company Dérivés d'isoquinoléine substitués utilisés en tant qu'immunomutateurs

Also Published As

Publication number Publication date
MD3980413T2 (ro) 2023-12-31
CA3138494A1 (fr) 2020-12-10
BR112021023780A2 (pt) 2022-01-11
AU2020286962A1 (en) 2022-02-03
KR20220017942A (ko) 2022-02-14
PL3980413T3 (pl) 2023-12-27
EP3980413C0 (fr) 2023-07-19
ES2956866T3 (es) 2023-12-29
EP3980413A1 (fr) 2022-04-13
CN113966329A (zh) 2022-01-21
RS64681B1 (sr) 2023-11-30
EP3980413B1 (fr) 2023-07-19
US20220259186A1 (en) 2022-08-18
MX2021015048A (es) 2022-01-18
HUE063236T2 (hu) 2024-01-28
JP2022535879A (ja) 2022-08-10
HRP20230873T1 (hr) 2024-02-16
MA56098A (fr) 2022-04-13
WO2020245372A1 (fr) 2020-12-10

Similar Documents

Publication Publication Date Title
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA44948A1 (fr) Inhibiteurs de bace 1
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA56098B1 (fr) Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes
MA51534B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA52220B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52565B1 (fr) Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1